相似文献
1
Blood and marrow transplant clinical trials network state of the Science Symposium 2014.
Biol Blood Marrow Transplant. 2015 Feb;21(2):202-24. doi: 10.1016/j.bbmt.2014.10.003. Epub 2014 Oct 15.
2
Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Biol Blood Marrow Transplant. 2020 Jul;26(7):1312-1317. doi: 10.1016/j.bbmt.2020.04.001. Epub 2020 Apr 10.
3
Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.
Haematologica. 2016 Feb;101(2):241-7. doi: 10.3324/haematol.2015.130401. Epub 2015 Nov 26.
4
Eosinophilia indicates the evolution to acute graft-versus-host disease.
Blood. 2002 Oct 15;100(8):3055. doi: 10.1182/blood-2002-04-1118.
5
6
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.
7
Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia.
Pediatr Blood Cancer. 2019 Jan;66(1):e27481. doi: 10.1002/pbc.27481. Epub 2018 Oct 14.
8
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.
9
Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
Blood. 2017 Jul 13;130(2):231. doi: 10.1182/blood-2017-04-779751.
10
Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Acta Haematol. 2021;144(1):66-73. doi: 10.1159/000507536. Epub 2020 May 19.
引用本文的文献
1
Modern-Era Challenges in the Clinical Management of Graft-Versus-Host Disease.
Adv Exp Med Biol. 2025;1475:103-128. doi: 10.1007/978-3-031-84988-6_6.
2
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.
Blood Adv. 2025 Jul 8;9(13):3268-3280. doi: 10.1182/bloodadvances.2025015793.
3
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Blood Adv. 2023 Sep 12;7(17):5189-5198. doi: 10.1182/bloodadvances.2023009853.
4
Hematopoietic Stem Cell Transplantation, Where Have We Come and Where Do We Go.
Blood Cell Ther. 2020 May 25;3(3):37-43. doi: 10.31547/bct-2019-016. eCollection 2020 Aug 25.
5
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.
Transplant Cell Ther. 2021 Nov;27(11):885-907. doi: 10.1016/j.jtct.2021.08.016. Epub 2021 Aug 27.
6
Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.
J Clin Oncol. 2021 Feb 10;39(5):534-544. doi: 10.1200/JCO.20.01623. Epub 2021 Jan 12.
7
Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.
Biol Blood Marrow Transplant. 2020 May;26(5):e94-e100. doi: 10.1016/j.bbmt.2020.01.024. Epub 2020 Feb 5.
8
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.
Blood. 2020 Jan 9;135(2):97-107. doi: 10.1182/blood.2019003125.
9
Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?
Curr Hematol Malig Rep. 2019 Feb;14(1):22-30. doi: 10.1007/s11899-019-0494-x.
10
Patient HLA Germline Variation and Transplant Survivorship.
J Clin Oncol. 2018 Aug 20;36(24):2524-2531. doi: 10.1200/JCO.2017.77.6534. Epub 2018 Jun 14.
本文引用的文献
1
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
J Clin Oncol. 2015 Dec 10;33(35):4167-75. doi: 10.1200/JCO.2015.62.7273. Epub 2015 Nov 2.
2
HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
Biol Blood Marrow Transplant. 2015 Oct;21(10):1783-9. doi: 10.1016/j.bbmt.2015.05.028. Epub 2015 Jun 6.
3
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.
Blood. 2015 May 7;125(19):2885-92. doi: 10.1182/blood-2015-01-607366. Epub 2015 Mar 16.
4
Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial.
Haematologica. 2015 Jun;100(6):842-8. doi: 10.3324/haematol.2014.118471. Epub 2015 Feb 14.
5
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
Blood. 2014 Oct 9;124(15):2354-61. doi: 10.1182/blood-2014-05-578963. Epub 2014 Aug 26.
6
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Blood. 2014 Aug 14;124(7):1047-55. doi: 10.1182/blood-2014-01-548941. Epub 2014 Jun 5.
7
Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol.
Biol Blood Marrow Transplant. 2014 Jun;20(6):858-64. doi: 10.1016/j.bbmt.2014.02.026. Epub 2014 Mar 7.
8
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
Blood. 2014 Mar 27;123(13):2017-25. doi: 10.1182/blood-2013-10-534297. Epub 2014 Feb 4.
9
Breakthrough of the year 2013. Cancer immunotherapy.
Science. 2013 Dec 20;342(6165):1432-3. doi: 10.1126/science.342.6165.1432.
10
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
J Clin Oncol. 2014 Mar 10;32(8):798-808. doi: 10.1200/JCO.2013.51.5304. Epub 2013 Dec 16.
Zotero 插件